Ribose Mediated Glycation of Human Serum Albumin and Their Inhibition by Silibinin and 2-Hydroxy-1,4-Naphthoquinone: In Vitro and Computational Studies
- 22 February 2025
- journal article
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 24 (07) , 965-983
Abstract
Under hyperglycemic conditions, proteins undergo structural modifications non-enzymatically, resulting in the formation of advanced glycation end products (AGEs). These AGEs contribute to the production of free radicals, which in turn exacerbate the development of diabetes and its complications. Therefore, inhibiting glycation is anticipated to play a crucial role in managing diabetes. Here, we have examined the effect of 2-hydroxy-1,4-naphthoquinone (NQ) and silibinin on ribose-mediated glycation of HSA. Presence of NQ and silibinin inhibited the fluorescent AGEs formation by 79.18% and 84.10%, respectively. Moreover, the secondary structural loss caused by glycation was restored by NQ and silibinin treatment. Both the compounds showed higher affinity toward native HSA compared to glycated HSA as evident from their binding constants. Molecular docking showed a direct interaction of tested compounds with glycation prone amino acids arginine and lysine residues of HSA. Molecular simulation studies confirmed the NQ or silibinin formed stable complex with HSA. Both the ligands formed hydrogen bonds throughout the trajectory. MM-PBSA calculation showed the overall binding energies for silibinin and NQ with HSA were −16.863 kcal/mol and −9.977 kcal/mol, respectively. The findings show the antiglycation potential of NQ and silibinin against ribose mediated glycation of HSA along with mode of action.Keywords
Funding Information
- Deanship of Scientific Research, King Saud University (RSP2025R352)
This publication has 54 references indexed in Scilit:
- Dietary advanced glycation end products and their relevance for human healthAgeing Research Reviews, 2018
- Targeting advanced glycation with pharmaceutical agents: where are we now?Glycoconjugate Journal, 2016
- Advanced glycation end products and diabetic retinopathyAmino Acids, 2011
- In vitro antiamyloidogenic properties of 1,4-naphthoquinonesBiochemical and Biophysical Research Communications, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Advanced Glycation End-Products and Arterial Stiffness in HypertensionAmerican Journal of Hypertension, 2007
- Synthesis and evaluation of antitumor activity of novel 1,4-Naphthoquinone derivatives (IV)Archives of Pharmacal Research, 2006
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy functionJournal of Computational Chemistry, 1998
- GROMACS: A message-passing parallel molecular dynamics implementationComputer Physics Communications, 1995